Below is where the judges will be focusing their scores. Write your entries accordingly.
Excellence in creating market and customer insight (15)
Clarity and appropriateness of objectives (10)
Quality of marketing strategy (15)
Quality of execution (15)
Quality of measurement and learning (10)
Evidence of improved health outcomes (15)
Creating Value (10)
This category relates to work in support of any drug for a rare disease or disorder or classified orphan drug at any phase of the product lifecycle.
Entrants will need to demonstrate a thorough understanding of the specific healthcare environment, show how they tailored their approach to the specific challenge of rare diseases/orphan drugs and show an appropriate approach to deliver value to stakeholders and so drive the business forward.
Judges are looking for evidence of true collaboration with patient groups and healthcare professionals/advocates.
Brands within the global markets, other European countries or UK are eligible.
The entry should relate to activities carried out between July 2017 and June 2019.
Entry deadline | 29 August 2019 |
Extended entry deadline | 5 September 2019* *additional fee applies |
Judging day | 26 September 2019 |
Company/Team Interviews | 9 October 2019 |
PMEA Event | 27 November 2019 |